Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411217 | 1.00 | EPHX1 (0.41) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL17781920 | 0.91 | APLNR (0.37) | EPHX1HPGDGPR119STSHSD17B10 | |
| SCHEMBL29083228 | 0.84 | EPHX1 (0.45) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL26171864 | 0.84 | EPHX1 (0.45) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL20583811 | 0.83 | KDM4E (0.55) | GPR119STSKDM4EPKMKMT2A | |
| SCHEMBL21649154 | 0.82 | EPHX1 (0.46) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL31734338 | 0.82 | EPHX1 (0.46) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL30368229 | 0.77 | STS (0.49) | GPR119STSKDM4EMAPTTHRB | |
| SCHEMBL31433654 | 0.77 | HPGD (0.44) | EPHX1HPGDGPR119RECQLSTS | |
| SCHEMBL31433665 | 0.77 | HPGD (0.44) | EPHX1HPGDGPR119RECQLSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4301468-A1 | FGFR3 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-117120439-A | FGFR3 inhibitor compounds | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2872501-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | Ares Trading S.A. (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | EPHX1 3046/4885HPGD 2512/4885GPR119 2204/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | EPHX1 4497/4885HPGD 4792/4885GPR119 3820/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | EPHX1 3046/4885HPGD 2512/4885GPR119 2204/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | EPHX1 3046/4885HPGD 2512/4885GPR119 2204/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | EPHX1 3046/4885HPGD 2512/4885GPR119 2204/4885 |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | EPHX1 1204/4885HPGD 267/4885GPR119 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.